Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive

Table 3 Additional secondary outcomes in the overall PS-trimmed and -matched populations

Outcome	PS-trimmed analysis^a			PS-matched analysis
Outcome	Abatacept (n = 170)	TNFi (n = 157)	p value^b	Abatacept (n = 111)	TNFi (n = 111)	p value^b
Response to therapy, Adjusted OR (95% CI)^c
Achievement of LDA	1.76 (0.53, 5.86)	Ref	0.36	1.55 (0.36, 6.64)	Ref	0.55
Achievement of remission	1.40 (0.56, 3.53)	Ref	0.47	1.58 (0.58, 4.34)	Ref	0.37
Drug retention
Patients who remained on drug at 6-month visit, n(%)	117 (68.82)	101 (64.33)	0.39	79 (71.17)	73 (65.77)	0.39

^aThe PS-trimmed cohort included patients with scores overlapping both populations
^bp values for secondary outcomes are from the adjusted mixed-effects models. Drug retention was assessed using the chi-square test
^cOR (95% CI) for difference between treatments at 6-month visit was adjusted for covariates where standardized difference remained imbalanced
LDA = Low Disease Activity; OR = Odds Ratio; PS = Propensity Score; Ref = Reference; TNFi = TNF Inhibitor
Adjusted variables for overall PS-trimmed and PS-matched cohort included a priori covariates CDAI, number prior biologics used, modified Charlson comorbidity index and current MTX use, and covariates that remained imbalanced– work status; for PS-trimmed only– gender, body weight, age at RA onset, RF+, patient reported pain and fatigue, and number prior csDMARDs; for PS-matched only– age, BMI, and current Prednisone use

ISSN: 2523-3106